Authors: Andras Vermes¹; Istvan Vermes²

Source: American Journal of Cardiovascular Drugs, Volume 4, Number 4, 2004 , pp. 247-255(9)

Publisher: Adis International

Abstract:

Adverse drug reactions are common; they are responsible for a number of debilitating side effects and are a significant cause of death following drug therapy. It is now clear that a significant proportion of these adverse drug reactions, as well as therapeutic failures, are caused by genetic polymorphism, genetically based interindividual differences in drug absorption, disposition, metabolism, or excretion. HMG-CoA reductase inhibitors are generally very well tolerated and easy to administer with good patient acceptance. There are only two uncommon but potentially serious adverse effects related to HMG-CoA reductase inhibitor therapy: hepatotoxicity and myopathy. The occurrence of lethal rhabdomyolysis in patients treated with cerivastatin has prompted concern on the part of physicians and patients regarding the tolerability of HMG-CoA reductase inhibitors. Apart from pravastatin and rosuvastatin, HMG-CoA reductase inhibitors are metabolized by the phase I cytochrome P450 (CYP) superfamily of drug metabolizing enzymes. The best-characterized pharmacogenetic polymorphisms are those within this enzyme family. One of these enzymes, CYP2D6, plays an important role in the metabolism of simvastatin. It has been shown that the cholesterol-lowering effect as well as the efficacy and tolerability of simvastatin is influenced by CYP2D6 genetic polymorphism. Because the different HMG-CoA reductase inhibitors differ, with respect to the degree of metabolism by the different CYP enzymes, genotyping may help to select the appropriate HMG-CoA reductase inhibitor and the optimal dosage during the start of the treatment and will allow for more efficient individual therapy. A detailed knowledge of the genetic basis of individual drug response is potentially of major clinical and economic importance.

Keywords: HMG CoA reductase inhibitors, general; Hepatic drug oxidation; Genetic polymorphism; Pharmacogenomics

Document Type: Review article

Affiliations: 1: 1 Department of Clinical Pharmacy, University Medical Center Rotterdam, Rotterdam, The Netherlands 2: 2 Department of Clinical Chemistry, Medical Spectrum Twente, Hospital Group, Enschede, The Netherlands

Publication date: 2004-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Cardiovascular Medicine ,  Pharmacology
• By this author: Andras Vermes ;  Istvan Vermes

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers